Supernus Pharmaceuticals Stock News

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MKM Partners' JC O'Hara says a simple strategy of picking the cheapest stocks at the start of the year, and then rebalancing, has been a winner through the years.

Equities analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to post sales of $146.74 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Supernus Pharmaceuticals earnings. The lowest sales estimate is $141.50 million and the highest is $150.04 million. Supernus Pharmaceuticals posted sales of $143.56 million during the same quarter []

Ziegler Capital Management LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 34.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,837 shares of the specialty pharmaceutical companys stock after acquiring an additional 9,362 shares during the quarter. Ziegler Capital Management LLC owned []

Zacks Investment Research cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several [] The post Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Hold at Zacks Investment Research appeared first on ETF Daily News .

Virginia Retirement Systems ET AL cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 19.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,300 shares of the specialty pharmaceutical companys stock after selling 5,500 shares during the quarter. Virginia Retirement Systems ET ALs []

Brokerages expect that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will announce $0.20 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Supernus Pharmaceuticals earnings. The highest EPS estimate is $0.35 and the lowest is $0.12. Supernus Pharmaceuticals posted earnings per share of $0.57 in the same quarter last year, which []

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) price on Friday, December 10, fall -3.18% below its previous days close as a downside momentum from buyers pushed the stocks value to $28.89. A look at the stocks price movement, the close in the last trading session was $29.84, moving within a range at $28.65 and $30.01. The beta value Major Improvements In Supernus Pharmaceuticals Inc. (SUPN) Stock Need To Be Considered Read More »

Franklin Street Advisors Inc. NC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 81.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,145 shares of the specialty pharmaceutical companys stock after buying an additional 18,000 shares during the []

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinsons Disease (PD).

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Equities researchers at Jefferies Financial Group lifted their FY2022 EPS estimates for Supernus Pharmaceuticals in a research note issued to investors on Wednesday, December 1st. Jefferies Financial Group analyst D. Steinberg now anticipates that the specialty pharmaceutical company will post earnings of $1.46 per share for the year, up from []

Equities researchers at Jefferies Financial Group started coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note issued to investors on Wednesday, The Fly reports. The firm set a buy rating and a $44.00 price target on the specialty pharmaceutical companys stock. Jefferies Financial Groups price target would indicate a potential upside of 41.12% [] The post Jefferies Financial Group Initiates Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN) appeared first on ETF Daily News .

Frontier Capital Management Co. LLC lowered its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 29.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 579,073 shares of the specialty pharmaceutical companys stock after selling 237,658 shares during the period. Frontier Capital Management []